After eight daunting months of battling COVID-19, there may be some light at the end of the tunnel as two potential vaccine candidates recently announced promising test results. 

Vaccines from Pfizer and Moderna are similar in that they both use emerging technology called messenger ribonucleic acid (mRNA) to reach nearly 95 percent efficacy. Typically, scientists create vaccines by using live or inactivated virus cells, which puts the actual disease into a person’s body. However, with mRNA technology, Pfizer and Moderna were able to avoid that. MRNA carries coded instructions that tell cells what defenses are necessary by appearing as a threat. 

Of Course, There's a Catch

The use of the molecule is groundbreaking for a number of reasons. One is the speed at which the vaccines were developed. The other is that the use of mRNA means the vaccines contain no infectious COVID-19 properties that could get patients sick. 

However, there is a drawback to the vaccines: they have to be stored in brutally cold temperatures.

Under normal circumstances, vaccines can survive when stored at around 40 degrees Fahrenheit, but for Moderna, the vials must be stored at -4 degrees.

For Pfizer's vaccine, the threshold for keeping an effective dose is even steeper at a staggering -94 degrees. The icy temperatures are necessary to keep the mRNA molecule intact, otherwise it “begins to fall apart and twist around in ways so that it doesn’t become effective,” a representative for the pharmaceutical giant told Cheddar.

Vaccine Storage & Distribution Roadblock

With the need for cold storage comes the obstacle of how to pull off widespread distribution. Most hospitals in the U.S. do not house facilities that meet the requirements to store either the Moderna or Pfizer vaccines for extended periods. Both vaccines are able to survive in typical storing temperatures of 35 to 46 degrees, but their shelf lives are limited that way.

For Pfizer, the vaccine would no longer be effective after five days in normal storage temperatures. Moderna, meanwhile, shows more promise when it comes to effective distribution as it’s vaccines appear to remain effective for a month while stored 35 degrees.

Pfizer has come up with a plan to ship its vaccine in boxes filled with dry ice. The vials will remain protected for up to 15 days -- but the container can only be opened up to two times per day. 

This could be a logistical nightmare for parts of the world that don't have sufficient equipment - or enough dry ice - to keep the vaccines. Even in rural America, many hospitals don't have freezers that can keep doses cold enough, particularly for the Pfizer vaccine.  

Getting Vaccinated

So what does this mean for you? Once the FDA approves emergency use authorization of either one or both of the vaccines, it looks like they will likely be distributed first among populations that need it the most: frontline healthcare workers, the elderly, and those suffering from underlying health conditions. 

Like several existing vaccinations for other conditions, both Pfizer and Moderna require two rounds of treatment in order for the body to build up complete immunity. For those receiving the Pfizer vaccine, patients will need to return for a second dose after three weeks and for those getting the Moderna vaccine, they'll have to go back for round two after four weeks. 

Video produced by Ali Larkin. Article written by Lawrence Banton.

Share:
More In Science
The Space Race In 2022
2021 was an exciting year for space innovations, but 2022 could hold even more in store. Cheddar took a deep dive into the space mission on tap for the year ahead.
U.S. Purchases 600K Doses of New Antibody Treatment Amid Omicron Surge
The United States purchased over 600,000 doses of a monoclonal antibody treatment from Glaxosmithkline and Vir Biotechnology, bringing the total worldwide doses purchased to 1.7 million. This comes as the country attempts to ramp up treatment options as cases of the omicron variant continue to surge. Dr. Asha Shah, Director of Infectious Diseases at Stamford Health joined Cheddar's Opening Bell to discuss.
2021: A Rebound of the Economy and Greenhouse Gas Emissions
As the pandemic slammed the brakes on the nation's economy in 2020, America's greenhouse gas emissions reached their lowest levels in at least three decades. However, as the world, and the economy re-opened, 2021 told a much different story as emissions surged. Biden's flagship 'Build Back Better' act involves billions in spending on electric cars and renewables, in an effort to cut U.S. emissions, experts are still skeptical that the nation will meet the current 2030 target. Andrew Dessler, professor of atmospheric sciences at Texas A&M University, joins Cheddar News.
Experts Debate Throat vs. Nasal Swabs for Omicron Testing
Amid the omicron surge, a new debate has emerged about whether or not throat swabs are more effective than nasal swabs for COVID testing. Dr. William Schaffner, MD, professor of infectious diseases, Vanderbilt Medical Center, sat down with Cheddar's News Wrap to weigh in on the dispute. "Should there be a change? You've got to do the studies, show that in the field [a throat swab] works as well or better than the nasal specimen," he said. "Let's not do it off our hips, as we say."
State of Emergency Declared in Virginia, as Multiple States Face Extreme Winter Weather
Virginia Governor Ralph Northam is declaring a state of emergency after Monday's winter storm left hundreds of drivers stranded on the interstate for more than 24 hours. The snow also knocked out power for many residents, with more than 100,000 outages remaining days later. Michael Wehner, a climate scientist at Lawrence Berkeley national laboratory, discusses recent weather disasters.
Walmart and Kroger Raise At-Home Covid Test Prices
As the need for COVID-19 testing increases, so does the price of the tests themselves. An agreement with The White House and several major companies to sell the tests at a lower cost has now expired, sending prices up as retailers struggle to keep kits on shelves. Dr. Thomas McGinn, executive VP of physician enterprise at Common Spirit Health, joins Cheddar News to discuss.
Emission Surge Puts U.S. Further Off Track from Climate Targets
A new report shows 2021 saw a surge in U.S. greenhouse gas emissions, indicating that the country remains far off track from meeting President Biden's climate change targets. Biden previously pledged to cut the nation's emissions in half by 2030, and now experts warn that immediate action must be taken in order to get the nation back on track. Zeke Hausfather, director of climate and energy at The Breakthrough Institute on U.S. Emissions and Global Temperatures, joins Cheddar News to discuss.
Toyota's Chief Scientist on Importance of Diversifying EV Fleets, Including Hybrid Models
Electric vehicles are quickly becoming an accessible way for consumers to slash emissions as legacy automakers begin to electrify their fleets and world leaders including President Joe Biden push for broad EV adoption. But consumers have concerns about EV range, the availability of charging stations, and more. What if it were both helpful to consumers — and feasible from a climate change standpoint — to keep hybrid models that run on gas on the market? Gill Pratt, CEO of the Toyota Research Institute & Toyota Motor Corporation's Chief Scientist joins Cheddar Climate to discuss his team's research about 'carbon return on investment,' how Toyota is electrifying its fleet, and more.
Major Cold Snap Settles Across Much of the U.S.
It's a painfully cold week across a large portion of the U.S. with more than 185 million Americans experiencing below-freezing temperatures on Monday and 10 million of them dealing with dangerous sub-zero temps.
Load More